News

FDA Awards Nearly $3 Million for TB Research


10 Oct 2010
by Working Group

This post originally appeared on Science Speaks.

US Food and Drug Administration
US Food and Drug Administration

The U.S. Food and Drug Administration (FDA) announced $2.9 million to support six research projects related to the diagnosis, treatment and prevention of tuberculosis on Monday.

This investment is a component of the FDA’s Critical Path Initiative (CPI) — a national strategy for transforming the way FDA-regulated products are developed, evaluated and manufactured. FDA launched the CPI in 2004 to address the decline in the number of innovative medical products being submitted for approval. One of the areas of CPI focus is new efforts to help meet unmet global public health needs. Beginning in 2010, CPI launched a new project aimed at enhancing the development and availability of diagnostics and therapies for tropical diseases, especially tuberculosis.

On March 19th, FDA Commissioner Hamburg and others announced a new collaboration to accelerate the development of combination treatments for tuberculosis. More information about the announcement can be found on the TB Alliance’s Critical Path to TB Regimens page.

Monday’s announcement includes grant awards made in the areas of TB vaccines, drugs and diagnostics.

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...